

# Ramon Palmero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2485591/publications.pdf>

Version: 2024-02-01

40  
papers

7,999  
citations

567144

15  
h-index

377752

34  
g-index

41  
all docs

41  
docs citations

41  
times ranked

8873  
citing authors

#	ARTICLE	IF	CITATIONS
1	Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. <i>Oncotarget</i> , 2022, 13, 812-827.	0.8	2
2	Multiplex RNA-based detection of clinically relevant <i>MET</i> alterations in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 350-363.	2.1	17
3	Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience. <i>Anti-Cancer Drugs</i> , 2021, 32, 88-94.	0.7	8
4	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 93-102.	1.5	31
5	Induction treatment in patients with stage III non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 539-554.	1.3	8
6	Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. , 2021, 9, e001601.		13
7	Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study. <i>Annals of Translational Medicine</i> , 2021, 9, 648-648.	0.7	2
8	Encephalitis Induced by Immune Checkpoint Inhibitors. <i>JAMA Neurology</i> , 2021, 78, 864.	4.5	61
9	Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. <i>Cancers</i> , 2021, 13, 4168.	1.7	8
10	Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2021, 125, 1365-1376.	2.9	8
11	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 416-425.	0.5	17
12	Severity of radiation pneumonitis, from clinical, dosimetric and biological features: a pilot study. <i>Radiation Oncology</i> , 2020, 15, 246.	1.2	9
13	Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. <i>Clinical Lung Cancer</i> , 2020, 21, 428-436.e2.	1.1	14
14	Mutations in the Antioxidant KEAP1/NRF2 Pathway Define an Aggressive Subset of NSCLC Resistant to Conventional Treatments. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1881-1883.	0.5	17
15	Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. <i>BMC Cancer</i> , 2019, 19, 165.	1.1	24
16	Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. <i>Endocrine</i> , 2019, 64, 605-613.	1.1	46
17	Tracking plasma KRAS mutations (mu) in lung adenocarcinoma (LUAC) patients (p) and branching evolution.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9055-9055.	0.8	0
18	Comment on an external validation of the 8th edition of the TNM classification for lung cancer staging in patients treated with chemoradiation. <i>Annals of Translational Medicine</i> , 2019, 7, S101-S101.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2018, 118, 639-647.	2.9	31
20	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 771-781.	5.2	167
21	Geriatric assessment to predict toxicity in elderly patients with unresectable locally advanced non-small-cell lung cancer treated with concurrent chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 8557-8557.	0.8	1
22	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	5.2	172
23	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. <i>Lung Cancer</i> , 2017, 108, 154-160.	0.9	18
24	Treatment of resectable stage IIIA non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 13-15.	0.6	3
25	Serum micronutrients and prealbumin during development and recovery of chemotherapy-induced peripheral neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2016, 21, 134-141.	1.4	10
26	A prospective study assessing the value of geriatric assessment in elderly patients with stage III NSCLC for concurrent chemoradiation. <i>Journal of Clinical Oncology</i> , 2016, 34, 8509-8509.	0.8	1
27	Duloxetine in symptomatic chemotherapy-induced peripheral neuropathy: Single-center experience beyond the clinical trial. <i>Journal of Clinical Oncology</i> , 2015, 33, e20713-e20713.	0.8	0
28	Clinical and therapeutic characteristics of patients died due to radiation-induced pneumonitis. , 2015, , .		0
29	PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors. <i>Cancer Biology and Medicine</i> , 2015, 12, 71-3.	1.4	7
30	Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1816-1820.	0.5	23
31	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. <i>Lung Cancer</i> , 2014, 84, 161-167.	0.9	81
32	Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL). <i>Journal of Clinical Oncology</i> , 2014, 32, 8079-8079.	0.8	4
33	Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL). <i>Journal of Clinical Oncology</i> , 2013, 31, 2581-2581.	0.8	3
34	Induction of an aggressive phenotype and poor survival in early-stage lung adenocarcinoma and epigenetic inactivation of microRNA-34b/c. <i>Journal of Clinical Oncology</i> , 2013, 31, 11056-11056.	0.8	0
35	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2012, 13, 239-246.	5.1	4,943
36	Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 69-74.	0.9	19

#	ARTICLE	IF	CITATIONS
37	Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report. <i>Head &amp; Neck Oncology</i> , 2010, 2, 3.	2.3	5
38	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 958-967.	13.9	2,213
39	Expression of cyclooxygenase-2 mRNA in peripheral blood of head and neck cancer patients and in healthy controls. A pilot study. <i>Acta Oto-Laryngologica</i> , 2007, 127, 71-75.	0.3	4
40	Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy. <i>World Journal of Surgical Oncology</i> , 2006, 4, 53.	0.8	6